7 results
Objectives: • To provide continuing treatment to subjects with SLE who complete HGS1006-C1056 or HGS1006-C1057.• To evaluate the long-term safety and tolerability of belimumab in subjects with SLE.
In this study, we aim to improve recognition of delirium in a palliative care population with advancedcancer and we aim to provide evidence for optimal treatment of delirium through adequate dosing ofpreferred neuroleptic.Primary objectives:1) To…
To evaluate whether preventive treament with haloperidol lowers the risk for delirium in stroke patients with an increased risk for delirium.
The current study is designed as a first exploration of this model. The hypothesis is that haloperidol will lead to an amelioration of the *psychotomimetic* effects of the THC-challenge.
The primary objective of this study is to test the hypothesis that discontinuation of antipsychotics does not lead to deterioration in functioning as measured by the ABC.
To study whether rivastigmine added to treatment with haloperidol shortens the duration of delirium in ICU patients and reduces costs.
To obtain a nonlinear mixed effects model (NONMEM) describing the population pharmacokinetics of haloperidol in the central (CSF) and peripheral compartment after oral and intravenous injection.